OLIDIA® PLLA Collagen Biostimulator (1 x 365 mg Vial) | DEFINE / PRAS (South Korea)

Short Description

A next-generation injectable Poly-L-Lactic Acid (PLLA) collagen biostimulator formulated as a 365 mg lyophilized powder vial (containing 150 mg of active spherical PLLA microparticles, 90 mg Sodium Carboxymethylcellulose, and 125 mg D-Mannitol). Engineered with uniform, smooth spherical microparticle morphology (40–63 µm), OLIDIA® provides improved particle suspension, rapid reconstitution, and low risk of nodule formation. Delivered into deep subcutaneous or supraperiosteal planes, it triggers sustained de novo Type I neocollagenesis, restoring lost facial volume, sharpening anatomical contours, and tightening lax tissue with clinical longevity lasting up to 24+ months.

Detailed Description

OLIDIA® is a sterile, non-pyrogenic, absorbable polymer biostimulatory implant manufactured in South Korea by PRAS Co., Ltd. / DEFINE. Designed as an advanced bio-equivalent alternative to first-generation PLLA injectables, OLIDIA refines the microparticle engineering process to optimize clinical handling, tissue integration, and safety.

While first-generation PLLA powders frequently feature irregularly shaped, jagged crystalline fragments that can cause mechanical micro-trauma, uneven distribution, and particle aggregation, OLIDIA utilizes controlled spherical microparticle synthesis:

• Uniform Particle Diameter (40–63 µm): The particles are calibrated strictly within the 40–63 micron range—large enough to escape immediate macrophage phagocytosis, yet small enough to glide effortlessly through thin-wall 25G or 27G microcannulas without clogging.

• Spherical Micro-Geometry: Smooth, rounded particle borders reduce local mechanical friction upon tissue contact, promoting a uniform, subclinical biological response without excessive foreign-body giant-cell reactions.

Tri-Phasic Mechanism of Action

1. Immediate Hydraulic Correction (Days 1–3): The sterile water and lidocaine vehicle fills structural hollows immediately post-injection. Within 48 to 72 hours, the aqueous vehicle is completely absorbed, returning tissue temporarily to near-baseline volume.

2. Controlled Subclinical Cellular Activation (Weeks 2–8): The evenly distributed spherical PLLA particles act as a biocompatible 3D scaffold. Host macrophages recruit resting dermal and subcutaneous fibroblasts, triggering progressive, high-yield synthesis of Type I collagen and surrounding extracellular matrix (ECM).

3. Hydrolytic Bio-Resorption & Native Redensification (Months 2–24+): The PLLA polymers slowly hydrolyze into non-toxic lactic acid monomers, which are metabolized into carbon dioxide ($CO_2$) and water ($H_2O$) via the endogenous Krebs cycle. Long after the synthetic microparticles are cleared, a dense, self-sustaining matrix of native collagen remains, preserving structural lift and tissue thickness.

Treatment Areas & Indications

• Midface Structural Volumization & Deep Atrophy:

  • Deep temporal fossa concavity and lateral eyebrow descent

  • Submalar cheek depressions, flattened malar apex, and midface fat-pad volume loss

  • Deep nasolabial fold effacement

• Lower Face Architecture & Vector Tightening:

  • Pre-jowl sulcus effacement and mandibular border definition

  • Chin shadow softening, mental crease structural correction, and marionette lines

  • Lateral cheek accordion smile lines and diffuse midface elastosis

• Neck & Décolletage Rejuvenation (Hyperdilute):

  • Transverse cervical wrinkles (“necklace bands”) and severe horizontal creasing

  • Décolleté solar elastosis and sleep-induced cleavage creases

• Non-Surgical Body Contouring & Skin Tightening:

  • Lateral pelvic depressions (hip dips) and biostimulatory gluteal volumization

  • Post-pregnancy periumbilical abdominal skin laxity and inner thigh crepeyness

  • Cellulite depression smoothing (subcision followed by hyperdilute PLLA fanning)

Key Clinical Advantages

• Uniform Spherical Particle Morphology: Smooth, rounded microparticles minimize shearing forces, ensuring homogenous tissue distribution and a low risk of late-onset subcutaneous nodules.

• Rapid Chairside Reconstitution: Unlike legacy PLLA powders requiring 24 to 48 hours of advance preparation, Olidia hydrates efficiently within 15 to 30 minutes (or via instant-shake protocols), streamlining clinic workflow.

• High Extrusion Smoothness: The spherical shape and optimized carboxymethylcellulose carrier prevent needle or cannula blockage, ensuring continuous, predictable extrusion force.

• High Biocompatibility & Safety: Synthesized from medical-grade, non-animal synthetic polymers with decades of safe clinical history in resorbable sutures and surgical plates; requires no prior allergy testing.

• Long Clinical Longevity: Stimulates the patient’s own fibroblasts to produce durable Type I collagen, sustaining aesthetic volume and dermal redensification for 24+ months.

Reconstitution & Preparation Protocols

To ensure homogenous particle suspension and prevent clumping:

[Olidia 365 mg Vial] + 5.0–7.0 mL SWFI ──► [Vigorous Agitation 1 Min] ──► Rest 15–20 Min ──► + 1.0–2.0 mL 2% Lidocaine

Technical Specifications

Comparative Benchmark: Olidia vs. Sculptra vs. AestheFill

Mandatory Post-Procedure Protocol: The 5-5-5 Rule

Because PLLA microparticles do not form a cross-linked gel matrix, physical mechanical dispersion post-treatment is essential:

• The 5-5-5 Rule: Instruct the patient to massage all treated areas for 5 minutes, 5 times per day, for 5 consecutive days.

• Clinical Purpose: Ensures the microparticles remain homogeneously distributed across subcutaneous planes, preventing focal particle aggregation and nodule formation.

• Technique: Firm, circular massage using a clean barrier cream or arnica gel.

Professional Advisory: OLIDIA® is a medical biostimulant intended strictly for certified dermatologists, plastic surgeons, and credentialed aesthetic physicians trained in microparticle suspension delivery and facial anatomy. Direct injection into the hyper-mobile vermilion lip body, the infraorbital tear trough, glabella, or superficial papillary dermis is strictly contraindicated due to the risk of visible, fibrotic nodule formation.